Of noteworthy, the results demonstrated that FoxM1 high mRNA expression was significantly correlated to shorter RFS in patients who have received treatments included endocrine therapy (HR = 2.35, p = 2.1e–11) (Figure 5G) or excluded endocrine therapy (HR = 1.39, p = 0.00017) (Figure 5H), especially in patients who treated with tamoxifen only (HR = 2.29, p = 4.7e-8) (Figure 5I), indicating a potential role of FoxM1 in contribution to tamoxifen resistance in breast cancer. Here, FOXM1 is linked to breast carcinoma.